Trump administration officials said they will begin developing a system for health insurers to disclose prescription drug prices, with a final plan hoped for by next May. The announcement was one of several biotech developments covered in STAT's The Readout newsletter.
In regulatory news, the FDA granted priority review to BridgeBio's oral treatment infigratinib for children with achondroplasia, a common form of dwarfism. An approval decision is expected by Feb. 4, 2027. Separately, Japan's Shionogi has agreed to acquire U.S.-based IntraBio for $2 billion; IntraBio makes an approved drug for the neurological symptoms of two rare diseases.
On the clinical trial front, Arrivent Biopharma said its experimental treatment for exon 20-mutated lung cancer failed to delay tumor progression in a Phase 3 study. The newsletter also noted that AstraZeneca has opened a new Boston site, and Utah is piloting an AI service to prescribe acne treatment.